Arena Pharmaceuticals Inc., of San Diego, said 2015 revenues totaled $38.3 million, including $19.7 million in net product sales of obesity drug Belviq (lorcaserin HCl). R&D expenses totaled $88.4 million while general and administrative expenses were $36 million. The company's net loss was $108 million, or 45 cents per share. For the fourth quarter, revenues totaled $7.8 million, including $3.9 million in Belviq net product sales. Net loss for the quarter was $30.5 million, or 13 cents per share. Arena reported cash and equivalents of $156.2 million as of Dec. 31, and approximately 242.9 million common shares outstanding. Although Arena reported IMS Health estimates of approximately 131,000 prescriptions for Belviq filled in the U.S. in the fourth quarter and partner Ildong Pharmaceutical Co. Ltd., of South Korea, estimates of approximately 2.4 million tablets of Belviq prescribed in South Korea – or approximately 40,000 one-month prescriptions – in the fourth quarter, the company declined to provide 2016 guidance for Belviq sales. On Tuesday, shares (NASDAQ:ARNA) closed at $1.53, up 4 cents.